GRIFFIN: Sustained responses of daratumumab plus RVd in MM Presented ByDr Jacob Laubach, Dana-Farber Cancer Institute, MA, USA TrialPhase 2, GRIFFIN ConferenceASH 2021 4 February, 2022 11:30